Identify and validate potential drug candidates from known antivirals and build translational understanding to support prediction of efficacy based on data from in vitro and in vivo pre-clinical models
current phase of drug development
updated 21 Apr 2021
DNDi is supporting the ANTICOV clinical trial by identifying and validating repurposed drug candidates, beginning with the in vitro and in vivo experimental work needed to provide supporting pre-clinical evidence. We are focusing mainly on compounds that have a direct-acting antiviral profile and on combinations of antivirals and anti-inflammatories.
COVID-19 is a new disease and has several phases – from an initial viral stage to a later inflammatory stage – which contributes to a lack of consensus understanding of the translational value of in vitro and in vivo experimental models. To help overcome this knowledge gap, our discovery team is also working to expand the translational understanding of how data generated in pre-clinical in vitro and in vivo models can help to predict the future efficacy of investigational drug candidates in patients.
Get our latest news, personal stories, research articles, and job opportunities.